Geneva Partners’s Astera Labs ALAB Stock Holding History

Geneva Partners’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,582	Closed	-$1.88M	–	83
2025 Q3	$1.88M	Buy	+9,582	New	+$1.58M	0.69%	37

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atreides Management Boston, Massachusetts $14.3B AUM 116.01% 1-Year Est. Return

Geneva Partners's ALAB Position: Q4 2025 in Review

Geneva Partners sold out of Astera Labs (ALAB) in Q4 2025, closing a stake of 9,582 shares — an estimated $1.88M sold.

Geneva Partners first reported a position in ALAB in Q3 2025 and held it in 1 quarter. The position peaked at $1.88M in Q3 2025. 701 funds tracked by Wall St. Rank hold ALAB as of Q4 2025.

Geneva Partners reported no remaining Astera Labs position as of Q4 2025 after selling out during the quarter.
Geneva Partners sold 9,582 Astera Labs shares in Q4 2025, an estimated $1.88M.
Geneva Partners first reported a position in Astera Labs in Q3 2025 and held it in 1 quarter.
Geneva Partners's Astera Labs position peaked at $1.88M in Q3 2025.
701 funds tracked by Wall St. Rank held Astera Labs as of Q4 2025.

Based on Geneva Partners's 13F filing for Q4 2025, filed 3 Feb 2026.